When: Confirmed breakout above $273 (upper Bollinger) with MACD histogram expanding above +1.0

Then: Upgrade to Hold

When: Talc litigation formally closed with plaintiff attorney sign-off removing tail risk

Then: Upgrade to Hold

When: Weekly close below $256.28 with volume expansion confirming technical break

Then: Reassess toward Sell

When: Major adverse talc verdict exceeding $5B framework settlement

Then: Reassess toward Sell

When: Forward EPS revision toward $10-11, signaling the 43% growth premium cannot be defended

Then: Reassess toward Sell

When: 10-Year Treasury yield falling materially below 4% AND MACD remaining negative

Then: Reassess toward Sell; would invert the income-rotation thesis

SELL with 25-40% trim, retaining 60-75% core position; reject aggressive underweighting, outright shorting, or paired ABBV/JNJ short trade

• Technical: MACD bearish cross typically allows 1-3 weeks of price holding before directional resolution; long-term trend intact with price 4% above 50 SMA, 14% above 200 SMA, golden cross structure holding
• Paired ABBV/JNJ short trade has asymmetric risks: shorting low-beta defensive stock (0.23 beta) during defensive rotation theme; both names fall together in risk-off; binary events like talc settlement could squeeze short leg
• Rotate-into-Treasuries macro bet: JNJ 2.0% yield vs 4.5% Treasuries assumes hawkish regime is permanent; 89% probability of zero cuts could flip quickly; missing equity recovery if Fed pivots dovishly within 12 months of labor weakness
• Balance sheet quality: Net debt-to-equity 35%; AAA credit rating intact; $24.5B operating cash flow; $19.3B free cash flow; net debt doubled to $28B is still manageable leverage
• Caplyta acquisition is strategic portfolio management replacing Stelara revenue facing biosimilar erosion with CNS franchise, not defensive desperation
• R&D decline from $17.2B to $14.7B reflects elevated 2024 spending on specific late-stage programs that have since read out; $14.7B remains massive by industry standards
• Icotyde cannibalization of Tremfya is strategic market capture allowing JNJ to own both oral and injectable formats in immunology rather than losing to competitors
• Conservative framework prioritizes drawdown minimization and participation in upside resolution over return maximization
• Market timing requires being right twice: exit timing AND re-entry timing; 60-75% retention avoids the dual-timing problem and cost of being out during recovery rallies
• Defensive 0.23 beta is structural insurance: in 2020, 2022, and every meaningful correction, JNJ underperformed on the way down by smaller margin than sector peers

→ vs aggressive: Long-term trend is NOT broken; price holding 4% above 50 SMA and 14% above 200 SMA; golden cross intact; MACD bearish cross historically allows 1-3 weeks of price holding before resolution

→ vs aggressive: Paired ABBV/JNJ trade has asymmetric risk profile: shorts low-beta defensive name against defensive rotation theme; both names fall together in risk-off; binary events like talc litigation settlement could cause 15% JNJ pop and implode short leg

→ vs aggressive: Rotate-into-Treasuries assumes hawkish regime permanence when 89% probability of zero cuts could flip fast; bond duration risk if Fed pivots dovishly within 12 months of labor weakness; missing equity recovery rally while waiting for $250 entry

→ vs aggressive: Fortress balance sheet not hollowed out: net debt-to-equity 35%, AAA rating intact, $24.5B operating cash flow, $19.3B free cash flow is not leveraged; Caplyta acquisition is good capital allocation not backfill desperation

→ vs aggressive: R&D decline from $17.2B to $14.7B reflects elevated 2024 late-stage program spending; $14.7B absolute base is still massive by industry standards

→ vs aggressive: Icotyde cannibalization of Tremfya is strategic market capture owning both oral and injectable formats, not a weakness; captures immunology market share regardless of format winner vs competitor erosion

Trim 30-35% of position; redeploy half into short-duration Treasuries, half into cash/defensive equity ETF; set re-entry triggers at 50 SMA ($257) or Bollinger middle ($263)

• Aggressive analyst correct that 2.0% JNJ yield vs 4.5% Treasuries is a structural disadvantage in hawkish regime with 89% odds of no 2026 cuts
• Paired trade (short JNJ/long ABBV) has asymmetric risk: both names fall in risk-off, JNJ's 0.23 beta is structural, and talc litigation resolution could pop JNJ 15% overnight
• Conservative analyst oversells the fortress balance sheet narrative: net debt doubled to $28 billion in one year, R&D spending declined materially, and M&A (Caplyta, Shockwave deals) creates execution risk
• 30.8x trailing P/E with 4.66 PEG ratio against 5.5% revenue growth does not justify 75% retained position near 52-week highs
• Bearish MACD cross has triggered; 50 SMA at $257 is 4% below current price, 200 SMA at $231 is 14% below
• Recommended redeployment: half of trimmed capital into short-duration Treasuries (income advantage), half into cash or defensive equity ETF (maintain sector exposure)
• Re-entry framework: add back on confirmed hold of 50 SMA at $257 with bullish reversal candle, or successful retest of Bollinger middle at $263
• Consensus SELL is well-supported by valuation stretch, technical deterioration, and yield disadvantage convergence

→ vs aggressive: Paired trade (short JNJ/long ABBV) is not a hedged structure—both names fall together in risk-off, JNJ's 0.23 beta makes it desirable in flight-to-quality scenarios, and binary event risk (talc litigation) is asymmetric with 15% upside overnight if resolved; treating this as clean arbitrage ignores three material risks

→ vs aggressive: Macro timing bet on hawkish regime permanence is not cleaner than market timing—if labor data softens or credit event occurs, the 89% prediction market odds re-price quickly and long-duration Treasuries become vulnerable to Fed pivot

→ vs conservative: 60-75% retained position in stock with 30.8x trailing P/E, 4.66 PEG ratio, and 5.5% revenue growth near 52-week highs with freshly triggered bearish MACD cross is not disciplined risk management—it's indecision dressed up as patience

→ vs conservative: Fortress balance sheet narrative ignores material structural changes: net debt doubled to $28 billion in single year, R&D spending declined, and intangible-heavy acquisitions are dominating capital allocation creating integration and pipeline translation risk